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Abstract
Background: Some areas of Africa are witnessing a malaria transition, in part due to escalated international donor
support and intervention coverage. Areas where declining malaria rates have been observed are largely
characterized by relatively low baseline transmission intensity and rapid scaling of interventions. Less well described
are changing patterns of malaria burden in areas of high parasite transmission and slower increases in control and
treatment access.
Methods: Uganda is a country predominantly characterized by intense, perennial malaria transmission. Monthly
pediatric admission data from five Ugandan hospitals and their catchments have been assembled retrospectively
across 11 years from January 1999 to December 2009. Malaria admission rates adjusted for changes in population
density within defined catchment areas were computed across three time periods that correspond to periods
where intervention coverage data exist and different treatment and prevention policies were operational. Time
series models were developed adjusting for variations in rainfall and hospital use to examine changes in malaria
hospitalization over 132 months. The temporal changes in factors that might explain changes in disease incidence
were qualitatively examined sequentially for each hospital setting and compared between hospital settings
Results: In four out of five sites there was a significant increase in malaria admission rates. Results from time series
models indicate a significant month-to-month increase in the mean malaria admission rates at four hospitals (trend
P < 0.001). At all hospitals malaria admissions had increased from 1999 by 47% to 350%. Observed changes in
intervention coverage within the catchments of each hospital showed a change in insecticide-treated net coverage
from <1% in 2000 to 33% by 2009 but accompanied by increases in access to nationally recommended drugs at
only two of the five hospital areas studied.
Conclusions: The declining malaria disease burden in some parts of Africa is not a universal phenomena across
the continent. Despite moderate increases in the coverage of measures to reduce infection and disease without
significant coincidental increasing access to effective medicines to treat disease may not lead to severe disease
burden reductions in high transmission areas of Africa. More data is needed from a wider range of malaria settings
to provide an honest tracking progress of the impact of scaled intervention coverage in Africa.
Background
Efforts to reduce the burden of malaria in Africa have
intensified through the scaled delivery of effective tools
for malaria prevention and disease management, facili-
tated by increased donor funding and a commitment by
national governments and their partners [1]. There have
been a number of reports of declining malaria morbidity
and mortality, in some cases directly or plausibly linked
to the scaling up of control efforts [2-13]. However,
many of these reports are from areas with relatively low
baseline malaria transmission intensity (South Africa;
large parts of Zambia, Ethiopia, Eritrea, Rwanda), island
communities (Zanzibar; Bioko, São Tomé and Príncipe),
or represent areas with a long history of malaria
research and surveillance systems (Kilifi, Kenya and The
Gambia). It is striking how little data have been pub-
lished from areas in Africa characterized by high
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any medium, provided the original work is properly cited.transmission and less intense rapid scaling of interven-
tion coverage.
In Kenya, following a nationally representative review
of pediatric malaria admissions to hospitals between
1999 and 2009 we noted that the declining incidence of
malaria admission was not a universal observation
across the country [8] despite relatively consistent tem-
poral increases in intervention coverage between sites
[9]. Kenyan hospitals where declining malaria admission
rates were far less notable, or showed evidence of
increasing with time, were located in areas with higher
malaria transmission intensity [9]. To extend the
empirical observations of possible temporal disease bur-
den changes in Africa across a wider range of transmis-
sion conditions and intervention coverage success, we
present data assembled from five hospital sites in
Uganda between 1999 and 2009 to improve our under-
standing of the proposed epidemiological transition in
Africa.
Methods
Ugandan malaria context
Uganda is a landlocked country traversed and bordered
by large inland water bodies. Plasmodium falciparum
transmission is intense and largely perennial and 1 of
the 15 highest transmission intensity countries world-
wide [14]. At 7 sites across Uganda entomological
inoculation rates (EIR) from locally dominant vectors,
mostly Anopheles gambiae s.s., ranged from 4 to over
1,500 infectious bites per person per annum [15], the
latter recorded at Apac represents the highest published
estimate of EIR in Africa. Areas with lower transmission
intensity are located along the high altitude areas bor-
dering Democratic Republic of Congo and Rwanda, the
slopes of Mount Elgon in the East, arid areas in the
North and the central areas of the urban extents of
Kampala [16-18]. The national estimate of age-under-5
mortality has been modeled to be approximately 145
per 1,000 live births for 2000 and predicted to have
declined to 117 per 1,000 live births by 2010 [19,20].
In 2001 a 5-year national malaria strategy was
launched, which had as its goal to ‘prevent and control
morbidity and mortality and to minimize social effects
and economic losses attributable to malaria in the coun-
try’ [21]. The strategy included one measurable health
outcome of reducing by 3% malaria case fatalities by
2005 and included a process outcome of ensuring that
at least 50% of children are protected by an insecticide-
treated net (ITN) by 2005 [21]. In 2005 the national
strategy was rewritten, retaining a similar goal but expli-
citly aiming to contribute to reducing age-under-5 mor-
tality from 152 to 103 per 1,000 live births with the
number of under 5 s protected by an ITN increased to
85% by 2010 [18].
Since 2004, three successful applications to the Global
Fund have resulted in approximately $200 million com-
mitted and $146 million disbursed to Uganda to support
a wide range of commodity needs and implementation
activities by the end of 2009 [22]. Between 2005 and
2009 the President’s Malaria Initiative (PMI) provided
$110 million to promote better coverage of insecticide
treated nets (ITN) though free distribution (since 2007),
mounting indoor-residual house-spraying activities in
selected districts and internally displaced camp popula-
tions, the nationwide improvement of malaria case man-
agement and drug management supply and improved
training for antenatal care providers to support intermit-
tent presumptive treatment [23]. UNICEF and bilateral
donors including the US pre-PMI, the UK, Belgium and
Canada have all contributed approximately $10.6 million
since 2004 for malaria control activities in Uganda [24].
Despite documented widespread chloroquine (CQ)
resistance across the East African region, including
Uganda, by 2001 [25,26], this drug was widely used in
combination with sulfadoxine-pyrimethamine (SP) as
first-line therapy in government clinics and promoted as
a national strategy to provide a home-based manage-
ment package (Homapak
®) between 2003 and 2005
[27-29]. Both CQ and SP clinical failure rates reached
exceptionally high levels by 2005 [30,31] and the policy
for malaria case management was finally changed in
April 2005. In 2006 the national malaria treatment
guidelines were revised to support the introduction of
artemether-lumefanthrine (AL) as first line therapy
[32-34] and effectively rolled out to all clinics by April
2006. However, AL funding, tendering and drug man-
agement supply to the periphery has been less than per-
fect since 2004 [35,36]. Between May and August 2007
it was shown that 75% of health facilities in four dis-
tricts had experienced a stock out of one of the four AL
packs, including 34% of facilities that had stocked out of
all treatment packs at least once simultaneously in the
preceding 6 months and 13% of facilities did not have
a n yA Lp a c k si ns t o c ko nt h ed a yo fs u r v e y[ 3 6 ] .T h e
early implementation problems may in part explain why
only 3% of fevers among children reported treatment
with AL in 2006 [37]. However, in 2008, between Sep-
tember and October 58% of the Public Health Facility
had experienced a stock out of at least one of the four
A Lp a c k si nt h e3m o n t h sp r i o rt os u r v e ya n do nt h e
survey day 17% were out of stock of at least one of the
four AL packs [38]. Private, retail sector availability of
AL or other artemisinin-based products is uncommon; a
study of 1,398 retail outlets across 38 districts in 2008
found no routine retail outlet stocked AL or any artemi-
sinin-based combination therapies (ACT) and only 4.3%
of drug stores stocked AL [38]. However in 2009 two
sample household surveys showed that 21% [39] and
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Page 2 of 1123% [40] of childhood fevers were treated with AL at
any time during the febrile illness occurring within the
last 2 weeks.
In 2000 less than 1% of Ugandan children were pro-
tected by an ITN [41,42]. Between 2001 and 2003 there
was a slow increase in activities to socially market or
use voucher schemes to promote ITN distribution, how-
ever, ITN coverage among children only marginally
increased to 9.7% during a national household sample
survey undertaken in 2006 [37]. From 2007, using PMI
support, free mass distribution campaigns and provision
free of charge of ITN to antenatal clinics has resulted in
an increase in children protected by ITN as evidenced
by the results of the most recent national household
sample survey undertaken in 2009 that showed ITN use
among children had risen to 32.8% [40]. Indoor residual
house spraying (IRS) activities have targeted areas of
unstable transmission including internally displaced per-
sons and refugee camps. Before 2006 IRS activities were
limited. The first large-scale pilot IRS campaign sup-
ported by PMI was introduced in the epidemic-prone
highland district of Kabale in 2006 and was subse-
quently repeated in 2007 and 2008 this time including
Kanungu district [43] and extended to several districts
in the North. From March to April 2008, pilot IRS cam-
paigns with DDT were carried out in the high transmis-
sion districts of Oyam and Apac and of the households
identified for spraying, it was reported that the cam-
paign covered over 90% of the targeted population [44].
Hospital selection
There are an estimated 65 government-supported hospi-
tals (2 national referral hospitals, 13 regional referral
hospitals and 50 general hospitals) providing inpatient
pediatric care services across Uganda. For this study five
relatively high pediatric admission burden hospitals were
identified in consultation with the Ministry of Health to
reflect the diversity of malaria transmission across
Uganda [15,45] and were most likely to provide records
of admissions over the last 11 years (Figure 1). The hos-
pital sites were representative of the national hospital
distribution and previous drug sensitivity district selec-
tions by the Ministry of Health [25], with the exception
that no hospital was selected in the concentrated urban
population living in Kampala. Mubende hospital is
located in a moderate-to-high transmission area of the
Central 2 region; Jinja is located in the East Central
region bordering Lake Victoria and represents an area
of historically moderate transmission and the hospital
serves a higher urban community than the other four
hospitals; Kambuga hospital in Kanungu district serves a
population that borders the Democratic Republic of
Congo in the South Western Region and characterized
by low, highland transmission intensity; Tororo is
situated in the Mid-Eastern region on the Kenyan bor-
der and supports high perennial transmission; and
finally Apac hospital is located centrally in the Mid-
Northern region and experiences exceptionally intense
transmission.
Pediatric admission data
Pediatric ward inpatient registers at all hospitals were
identified for most months from January 1999 to
December 2009. Each admission entry in the registers
was recorded on a tally sheet indicating the month of
admission and whether an admission diagnosis of
malaria had been defined for the child or whether the
admission diagnosis did not include an indication of
malaria.
Exact dates of birth were not available for all admis-
sions and we have assumed all pediatric admissions
were aged between 0 and <15 years. Individual register
entries were not reconciled with patient notes and we
have assumed that the admission diagnosis remained
the diagnosis upon which each admission was managed
clinically. Slide confirmed malaria diagnoses at admis-
sion were not universally available within and between
hospital sites for the surveillance period and this con-
tinues to pose a significant information gap [46]. There-
fore our working definitions of ‘malaria’ were patients
admitted with a diagnosis of malaria, probably managed
clinically as malaria during their admission but without
documented parasitological confirmation.
For each possible 132-month series at each hospital,
data were missing for 6 months (5%) at Jinja, 8 months
(6%) at Kambuga, 13 months (10%) at Tororo, 14
months (11%) at Mubende and 21 months (16%) at
Apac because registers were missing or torn. The miss-
ing data were handled using the ‘ice’ command in Stata
(v.11.1; Stata, College Station, TX, USA) by creating
multiple imputed data sets for missing values using
other existing variables and prior information (the num-
ber of malaria and non-malaria deaths or admission as
appropriate) to create an imputed value for each of the
missing months. The same algorithm was used across
all sites with all missing data imputations performed per
sites (that is, using data from that site only).
It is important to standardize changing admission
rates with time between hospitals with respect to the
catchment population and natural growth in populations
served by each hospital. Defining precise catchment
areas is non-trivial and we have previously used
addresses of pediatric admissions to explore the spatial
nature and form of catchment areas at 17 Kenyan hospi-
tals [8]. Similar information and detailed, high-resolu-
tion settlement mapping were not available in Uganda.
We have therefore used an average radial distance of 30
km (that captured over 90% of admissions in Kenya) for
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five Ugandan hospital sites. With the exception of Jinja,
which is a regional referral hospital, all the others are
district hospitals and the defined catchment area are
inclusive of the subcounties where health workers in
each hospital say majority of their patients originate.
This radial boundary was used in combination with a
100 × 100 m human population density map developed
from fine resolution satellite imagery, land cover and
available information on human population counts from
the highest resolution census administration boundaries
[47,48]. Population counts within a 30 km radius of
each hospital were extracted in ARCGIS 9.2 (ESRI, Inc.,
Redland, CA, USA) for the Ugandan census date of
2002. Other methods have been used elsewhere [8] to
define catchment populations but depend on the avail-
ability of reliable data on residential location of admitted
patients. There is remarkably little published data on
distances travelled for severe illness requiring hospitali-
zation and this is an area that demands further investi-
g a t i o n .M e a n w h i l e ,3 0k mh a sb e e ns h o w nt ob ea
reasoned catchment distance for hospitals in Kenya and
therefore elected for use here in Uganda. District-speci-
fic population age structures and natural annualized
growth rates [49] were used to project forwards and
backwards to provide an estimated 0-14-year-old popu-
lation estimate for each of the survey years 1999
through to 2009. Malaria and non-malaria incidence
was computed using the estimated children aged 0-14
years resident in the hospital catchment area. Confi-
dence intervals around each annualized admission rate
per 1,000 children aged 0-14 years were computed using
the Poisson distributions [50].
In addition we have collapsed average annualized
admission incidence rates across three key time periods:
(a) a period that corresponds to the widespread use of
CQ-SP, little progress toward scaled ITN/IRS coverage
and limited external donor financial support (1999-
2003); (b) a period of transition to AL implementation,
moderate increases in ITN coverage and improved
external donor assistance (2004-2006); and finally (c) a
period that witnessed a large increase in external
Figure 1 Monthly cases of malaria admission.A1 0 0×1 0 0mh u m a np o p u l a t i o nd e n s i t ym a pd eveloped from fine resolution satellite
imagery, land cover and available information on human population counts from the highest resolution census administration boundaries
showing the catchment areas around each hospital [47,48]. Graph panels show monthly cases of malaria admissions observed (black bars) and
imputed (gray bars) across the 11-year period.
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Page 4 of 11funding from The Global Fund to Fight AIDS, Tubercu-
losis and Malaria (GFATM) and PMI, a concerted effort
to provide free ITN distribution including mass cam-
paigns in 2007, the introduction of IRS in selected dis-
tricts (including Apac and Kanungu) and an established
single recommendation for AL and a withdrawal of CQ-
SP (2007-2009). Furthermore, data on the coverage of
interventions during these periods are available from
geolocated cluster sample survey data from national sur-
veys to explore the plausible correspondence between
changing prevention and case management strategies
and disease incidence between time intervals and
between hospital settings (Table 1).
Time series analysis
To examine the long-term trends in admission rates we
used monthly malaria admission data, standardized for
under 15 population densities within each catchment
areas, with moving average smoothing methods to iden-
tify any long-term trend signals within each temporal
11-year series while filtering o u ts h o r t - t e r ma n n u a lf l u c -
tuations and random variation. The smoothing technique
Table 1 Hospitalization and intervention characteristics of selected study regions
Characteristic District (region)
Kambugu
Hospital
(South
Western)
Mubende
Hospital
(Central 2)
Jinja
Hospital
(East
Central)
Tororo
Hospital
(Mid-
Eastern)
Apac
Hospital
(Mid-
Northern)
Number of beds 135 100 431 285 100
Projected population <15 years in 30 km radial catchment:
1999 235,448 116,802 398,969 310,100 116,910
2009 280,321 159,316 522,751 413,633 166,559
Average annual rainfall 1999-2009, mm 1,009 1,062 1,359 1,553 1,471
Malaria admission rate per 1,000 catchment of 0-14-year-old population per
year 1999-2009
(95% CI),
total malaria records
6.85
(6.76 to 6.95),
19,398
9.20
(9.04 to 9.35),
13,860
8.71
(8.62 to
8.80),
39,355
12.49
(12.38 to
12.60),
49,413
20.30
(20.07 to
20.52),
31,351
Non-malaria admission rate per 1,000 catchment of 0-14-year-old
population per year 1999-2009
(95% CI),
total non-malaria records
1.41
(1.37 to 1.46),
7,607
5.05
(4.94 to 5.16),
7,607
4.34
(4.28 to
4.40),
19,622
2.93
(2.88 to
2.98),
11,595
11.63
(11.46 to
11.81),
17,970
Intervention coverage:
a
UDHS 2000/2001
Percentage of children under 5 years with fever treated with
recommended first-line drug CQ (n)
10.4 (316) 10.2 (206) 25.0 (356) 17.6 (278) 9.6 (187)
Percentage ITN coverage in children aged <5 years
b (n) 0.15 (1374) 0.92 (649) 0.36 (845) 0.73 (683) 0.50 (399)
UDHS 2006
Percentage of children under 5 years with fever treated with
recommended first-line drug CQ + SP (n)
19.5 (205) 8.3 (240) 9.6 (374) 8.4 (346) 16.8 (499)
Percentage ITN coverage in children aged <5 years
b (n) 7.1 (917) 4.2 (793) 5.0 (925) 6.5 (799) 23.1 (1063)
UMIS 2009
Percentage of children under 5 years with fever treated with
recommended first-line drug AL (n)
10.0 (106) 18.0 (158) 13.4 (322) 16.6 (130) 40.8 (361)
Percentage ITN coverage in children aged <5 years
b (n) 32.6 (487) 11.3 (352) 18.9 (564) 41.8 (479) 41.8 (568)
Proportion of households sprayed in last 12 months (n) 1.8 (705) 4.6 (439) 0.4 (557) 0.6 (530) 31.6 (552)
Transmission intensity at end of surveillance period 2009
Parasite rate among children aged 1-59 months November-December 2009
(n)
11.6% (460) 50.7% (344) 56.3%
(538)
37.5% (472) 62.5% (554)
aIndividual level data from the Uganda Malaria Indicator Survey (UMIS) undertaken between November and December 2009 was not available at the time of
publication thus we have resorted to reporting regional estimates. The sample was stratified into nine survey regions across the country, plus Kampala.
Individual-level data from the Uganda Demographic and Health Surveys (UDHS) undertaken in September-March 2000/2001, May-October 2006 data were
reconstructed from empirical data available at http://www.measuredhs.org/ and extracted to correspond to intervention coverage within the regions used in the
MIS 2009.
bInsecticide-treated net (ITN) coverage was defined as the percentage of children aged under 5 who slept under an ITN last night and a treated net defineda s
one that was long lasting or had been soaked or dipped in insecticide in last 6 months.
AL = artemether-lumefanthrine; CQ = chloroquine; SP = sulfadoxine-pyrimethamine;.
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by n neighboring elements, where n is the width of the
smoothing ‘window’ equal to 12 months. We employed a
centered moving average including six observations
b e f o r ea n df i v ea f t e rt h et i m ep o i n ta n dv i c ev e r s a ,a n d
taking an average value of this to compute the centered
average. The ARMAX (’AutoRegressive Moving Average
model with eXogenous inputs’)m o d e lw a st h e na p p l i e d
[51], which is an autoregressive model of the empirical
current value of the series against one or more prior
values combined with a moving average of the current
value modeled against the white noise (random shocks)
of one or more prior values and includes explanatory
variables. The established explanatory variables for
malaria trend analysis included rainfall in the preceding
months (at different significant timelags), assembled
from meteorological stations located close to each hospi-
tal, and changes in service use (captured by non-malaria
admission rates) resulting in a predicted or smoothed
malaria admission rate per month for each hospital site
over the period 1999 to 2009. Correlations between rain-
fall at different timelags and malaria cases were assessed
before including significant variables in the final ARMAX
model. Before specifying the ARMAX model, tests and
diagnostics were performed in the estimation of the mod-
els. Monthly malaria rates were tested for stationarity
using the augmented Dickey-Fuller test [52] with a lag of
12 months. Model diagnostics and selection criteria were
used to determine the most parsimonious model. Two
goodness-of-fit criteria were used to guide model selec-
tion: Akaike information criterion (AIC) and Schwartz’s
Bayesian information criterion (BIC). The models with
the lowest AIC and BIC were finally selected. All analysis
was undertaken using Stata V. 11.0.
Results
Descriptions of hospital data
Information was assembled on 146,473 (72%) malaria
admissions and 58,115 (28%)a d m i s s i o n sw h e r ead i a g -
nosis of malaria was not made at admission among chil-
dren aged less than 15 years of age at the 5 hospitals
over 11 years (January 1999-December 2009). Corrected
malaria admission rates standardized for population esti-
mates within each hospital catchment over the entire
period varied between hospital sites, ranging from 6.9
per 1,000 children 0-14 years per year in Kambuga to
20.3 per 1,000 children per year in Apac (Table 1).
These differences between hospitals were similar
between the three important time periods and none of
the annualized period incidence estimates were signifi-
cantly different between time periods within each hospi-
tal site with the exception of a higher incidence at
Kambuga during the second period (2004-2006) and a
general tendency at all sites for the malaria admission
rates to be higher in the last period, 2007-2009, com-
pared to the first period 1999-2003 (Table 2). Non-
malaria admission rates across the three time periods
demonstrated either no changes at Mubende and Kam-
buga, a slight increase at Tororo and marginal declines
at Jinja and Apac. With the exception of one period in
Jinja, none of these differences were significant with
overlapping confidence intervals in all estimated time
period rates (Table 2).
To examine the long-term temporal signals within the
monthly time series several model forms were explored.
The predictions from the best fitting model that
adjusted for non-malaria admission rates and rainfall at
different lags while controlling for autoregressive and
moving average effect within the data are shown in Fig-
ure 2. We included linear trend lines fitted to estimated
average monthly changes in malaria admissions. The
relationship between malaria admissions by month show
increases across all five sites, although this appears less
clear in Kambuga where there were exceptional peaks in
malaria admission rates in 2005/2006. Significant (P <
0.001) upward trends in malaria admission rates were
observed in Mubende, Jinja, Tororo and Apac over the
study period (Figure 2). By 2009 the relative propor-
tional increase in malaria admission cases from 1999
was greatest in Mubende (+350%) with a significant
peak in 2009, but important increases were seen in all
other sites when compared to 1999 at Jinja (+200%),
Tororo (+200%), Apac (+188%) and Kambuga (+47%)
(Figure 1).
Discussion
Across all five hospital sites investigated, malaria admis-
sion rates have increased or remained unchanged since
the period of prescaled intervention and funding (1999-
2003) through a period when Uganda had received sig-
nificant overseas donor support (2007-2009). Conversely
non-malaria pediatric admissions remained relatively
constant across all three observation periods 1999-2003,
2004-2006 and 2007-2009 (Table 2). Analysis of
monthly time series of malaria admission rates using
autoregressive models adjusting for external factors
show that there was a significant increase in pediatric
admissions from January 1999 to December 2009 (Fig-
ure 2; all linear fits P < 0.001) in four of the five sites.
The net, proportional increases across all sites in
malaria admissions from the beginning of 1999 to the
end of 2009 ranged from 47% to over 350% depending
on the hospital site. For example in Apac the proportion
of malaria admissions was 54% in 1999 and increased to
70% by 2009 while in Jinja the proportion of malaria
admissions increased from 49% to 73%.
We have adjusted for a number of factors that might
influence a rising temporal hospital presentation of
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pediatric population’s served by each hospital, between
yearly seasonal variations in rainfall patterns and a
proxy for overall hospital use through the adjustment
for admissions not diagnosed as malaria. It seems there-
fore entirely plausible that malaria admissions have risen
in four of the five sites included in the analysis. The site
located in an area of lower transmission intensity
experienced a large ‘epidemic’ period of malaria between
2005 and 2006 that distorted the linear time series ana-
lysis, however even at Kambugu the average malaria
admission incidence between 1999-2003 was not signifi-
cantly different from the period after large funding and
implementation activities 2007-2009 (Table 2).
We have not been able to adjust for the proportion of
true malaria diagnoses among children admitted to each
hospital or changing diagnostic practices that may create
a systematic bias in observed trends. This presents a
perennial problem for all retrospective hospital reviews
where parasitological diagnoses are not available for sys-
tematic review or data linkage. Nevertheless similar
reviews of admission records, with similar caveats, have
been used repeatedly to support claims of declining inci-
dence of malaria admissions [7,8,10,11,53,54] and there-
fore should be viewed with equivalent validity for
increasing incidence. Changing practices and support to
improve the diagnosis of malaria with time are likely to
have resulted in fewer false positives and therefore one
Table 2 Temporally aggregated pediatric admission data for malaria each of the five hospitals between 1999-2003,
2004-2006 and 2007-2009 expressed per 1,000 children aged 0-14 years at risk per annum and 95% confidence
intervals computed using a Poisson distribution
Hospital location Kambuga Mubende Jinja Tororo Apac
Average annual malaria admission rate 1999-2003 (95% CI),
total number of malaria admissions
4.79 (4.52 to
5.07), 5,846
7.80 (6.62 to
7.56), 4,448
5.93 (5.70 to
6.16), 12,570
9.56 (9.23 to
9.89), 15,899
17.18 (16.47 to
17.92), 10,879
Average annual malaria admission rate 2004-2006 (95% CI),
total number of malaria admissions
11.95 (11.54 to
12.37), 9,372
10.39 (9.86 to
10.93), 4,374
7.89 (7.63 to
8.14), 11,114
14.74 (14.35 to
15.14), 16,332
22.04 (21.28 to
22.82), 9,602
Average annual malaria admission rate 2007-2009 (95% CI),
total number of malaria admissions
5.06 (4.80 to
5.33), 4,180
10.84 (10.33 to
11.36), 5,038
10.25 (9.98 to
10.53), 15,671
14.20 (13.84 to
14.58), 17,182
22.56 (21.84 to
23.30), 10,870
Average annual non-malaria admission rate 1999-2003 (95%
CI), total number of non-malaria admissions
1.50 (1.35 to
1.66), 1,823
4.82 (4.44 to
5.23), 3,000
4.69 (4.49 to
4.90), 9,880
2.89 (2.71 to
3.08), 4,729
11.89 (11.27 to
12.47), 5,328
Average annual non-malaria admission rate 2004-2006 (95%
CI), total number of non-malaria admissions
1.50 (1.35 to
1.65), 1,176
5.08 (4.71 to
5.47), 2,142
3.25 (3.09 to
3.41), 4,568
2.32 (2.16 to
2.48), 2,570
10.67 (11.66 to
12.80), 5,328
Average annual non-malaria admission rate 2007-2009 (95%
CI), total number of non-malaria admissions
1.21 (1.08 to
1.34), 998
5.31 (4.96 to
5.69), 2,465
3.38 (3.22 to
3.54), 5,174
3.59 (3.41 to
3.78), 4,296
10.67 (10.18 to
11.18), 5,119
Figure 2 Model predictions of malaria hospitalization rates. Plots of model predictions of malaria hospitalization rates controlling for lagged
rainfall and non-malaria cases and controlling for autoregressive and moving average effects (solid black line) and observed malaria
hospitalization rates (green dotted line). Fitted lines illustrate the linear trends from model predictions (dashed line).
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malaria diagnosed admissions.
Despite the incomplete nature of centrally reported
hospital admission data, the national Health Information
Systems (HMIS) of the Ugandan Ministry of Health sug-
gest that the malaria case burden in public health facil-
ities has increased from 3.5 million in 2000 to 10.7
m i l l i o ni n2 0 0 4a n dr i s e nf u r t h e rb y2 0 0 8t oo v e r1 2 . 2
million cases [46]. Although HMIS data are plagued by
gaps and changes in reporting rates between and within
years, these parallel data circumstantially support a ris-
ing, rather than declining, trend in malaria burden in
Uganda. User fees in government health facilities were
abolished in 2000, thus potentially creating a systematic
bias in observed trends but the increasing trends
remained significant after adjusting for non-malaria
cases used here as a proxy for changes in hospital usage.
Uganda has been granted almost $267 million in over-
seas donor assistance since 2002 and this has translated
into an average annual external commitment to malaria
funding of approximately $2 per person at risk in
Uganda [24], within $0.5 of requirements predicted to
provide sufficient funding for a complete package of
intervention delivery [55]. National coverage with essen-
tial interventions remains below international targets set
10 years ago in Abuja, Nigeria [56] and those set by
national malaria strategies launched in 2001 and 2005
covering 5-year periods, respectively [18,21]. By 2009
the proportion of children sleeping under an ITN was
only 33% and less than a quarter of children with a feb-
rile illness had access to the nationally recommended
first-line treatment. However, there are important differ-
ences in intervention coverage between districts that are
served by the five hospitals included in this study (Table
1). At Apac and Tororo, two focus districts for PMI
support, ITN coverage among children exceeded 40% by
2009 while it was less than 20% in Mubende and Jinja
districts. However it is important to consider all facets
of malaria control and while ITN and IRS coverage has
improved with time, the proportion of febrile children
who access efficacious, recommended antimalarial drugs
has declined. In 2000, access to CQ was equivalent to
the access reported in 2009 to AL in three of the five
study areas shown in Table 1. However over 40% of feb-
rile children living in the area around Apac were treated
with AL in 2009 while all other districts only managed
to report less than 20% use of AL in 2009 [40]. Despite
these differences and the combined efforts to provide
IRS with PMI support in Apac, increasing intervention
coverage has yet to translate into observed reductions in
hospitalization. Uganda is still characterized by predomi-
nantly high malaria transmission intensity, as judged by
t h ep a r a s i t ep r e v a l e n c er e c o r d e di nc h i l d r e na g e dl e s s
than 5 years. By the end of the surveillance period
transmission intensity remained high across Mubende,
Jinja, Tororo and notably high at Apac but low in Kam-
bugu (Table 1).
It is important to begin to define why large-scale
donor support has not translated into significant inter-
vention coverage. There were concerns about the trans-
parent use of GFATM funding in Uganda that led to
suspension of funding in August 2005 and led to the
interruption in funding flows and planned activities [57].
Procurement and provision of effective medicines
through responsive drug management supply chains has
been the subject of international concern around tender-
ing processes [35,58,59] and documented shortages of
malaria medicines in the periphery [36,38]. In the 1980s
and 1990s many settings witnessed an increase in
malaria cases as a result of increasing resistance and
declining efficacy of antimalarial drugs. This status quo
is perpetuated today where despite the existence of
more efficacious drugs these are far from universally
available resulting in an overall population effectiveness
of effective treatment that could perpetuate a continued
rise in disease incidence despite only moderate increases
in ITN coverage. The preferred options for delivering
ITN remained anchored in client payment systems for
many years, albeit subsidized, but not free until late in
2007. Mass ITN distribution campaigns however have
not raised coverage to effective levels anticipated to
impact upon transmission [60]. The current level of
ITN coverage is inadequate to significantly impact on
disease incidence given the levels of high transmission
intensity that characterize Uganda [60]. Additionally, six
different national malaria control program managers
have been appointed over the last 10 years and this has
inevitably resulted in a loss of institutional memory and
consistent stewardship. Despite these shortfalls in
malaria control implementation since 2004 the Ugandan
national malaria strategy for 2011-2015 has as its vision
that ‘malaria will no longer be the major cause of illness
and death in Uganda and families will have universal
access to malaria prevention as well as treatment by
2015’ supported by a mission statement that states that
the Ministry and its partners will ‘reduce the level of
malaria infection and consequent malaria death in
Uganda by 75% by the year 2015, and to sustain that
improved level of control to 2020’.
There is a general sense that all of Africa is witnessing
an epidemiological transition that is a direct result of
international donor support [61]. This position has been
supported by recent reports of a declining malaria inci-
dence across a number of sites in sub-Saharan Africa
[2-8,10-13,53,62,63] and modeled predictions of the
malaria-specific mortality effect size of increased inter-
vention coverage [61,64]. However, as noted in a recent
review of the evidence, that still supported the view that
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incidence across Africa, there remains a publication bias
in favor of ‘good news stories’ [65] from areas of tradi-
tionally low transmission intensity and rapid, concerted
scaling of disease prevention and management strategies.
The modeling exercises that use the Lives Saved Tool
(LiST) [61,64,66,67] make various assumptions about
the impact size derived from randomized controlled
trials [68] on a fraction of age-under-5 mortality pre-
sumed to be malaria from verbal autopsy studies [69].
The LiST model does not account for variations in
either intervention effect size or malaria burden by
malaria transmission intensity. The predicted impacts
on under-5 mortality are also based on single interven-
tion effect sizes, for example the expected numbers of
deaths averted defined by the protective efficacy of ITN
and the proportion of children sleeping under an ITN.
What the models do not accommodate are the simulta-
neous effects of increasing ITN coverage and declining
access to effective medicines when children are febrile.
In areas of high parasite transmission these combined
effects may cancel, or increase severe complications
leading to hospitalization or death.
Given the retrospective nature of hospital admissions
to define historical trends there are a number of impor-
tant caveats. First, inadequacies in routine hospital infor-
mation systems plague many countries in sub-Saharan
Africa and it remains difficult to identify hospitals with
complete records covering 10 complete years. We have
attempted to locate hospitals in representative malaria
ecological settings that did have reasonable recording
systems since 1999 and were therefore purposive rather
than random in our selection of hospital sites. However,
any bias would have favored better performing hospitals
more likely to disprove any notion of increasing malaria
trends and there was no prior expectation that admis-
sions would increase. Second, despite a rapid increase in
donor financing of malaria control in Uganda since
2005 there has not been an equivalent investment in
monitoring the impact on transmission through routine
parasitological or entomological surveillance. Entomolo-
gical inoculation rates were high in almost all the sites
investigated during the late 1990s [15] and childhood
parasite prevalence was high at the end of the surveil-
l a n c ep e r i o di n2 0 0 9( T a b l e1 )o f f e r i n go n l yas u g g e s -
tion, rather than an empirical description that there has
been little change in transmission. Third, because of a
lack of longitudinal, high resolution data on the cover-
a g eo fI T N ,I R So ru s eo fe f f e c t i v em e d i c i n e st ot r e a t
fever any attempt to attribute admission impact to chan-
ging intervention coverage through a plausibility frame-
work is weakened by inadequate spatial and temporally
resolved data. Finally, intriguing observations, whether
they be declining or increasing disease incidence raise a
number of important questions which unfortunately we
and many others are unable to address retrospectively
including the relative impacts of first line drug effective-
ness with time, the changing patterns of alternative uses
of clinical care providers in the community, the precise
changing boundaries of catchment populations to hospi-
tals within an area, patterns of resistance and tolerance
to insecticides by dominant vector populations and
many other factors that contribute to epidemiological
transitions.
The problems facing analysis of available data on
malaria trends in Africa are generic and not specific to
the study presented here. However there is a concern
that a more realistic assessment of the public health
impact of scaled malaria control is constrained by the
selective nature of reporting only ‘good news’ stories by
donor agencies. Despite the limitations of historical
reviews a more systematic country-level meta-analysis of
available data is required to provide a more comprehen-
sive understanding of the epidemiological transition in
Africa and notably from areas that have the highest
transmission intensity. These reviews should begin to
explore the wealth of national data on intervention cov-
erage, mortality and financing but must be undertaken
subnationally to reflect the diversity of malaria risks
common to most countries. Linkage to combined inter-
v e n t i o na c c e s si sn o n - t r i v i a lb u tw i t hm o r ed a t ai nt i m e
and space a clearer, less simplistic model of attribution
might be possible. Without detailed observational epide-
miology claims of success and the platform to decide
upon future investments in control and new disease-pre-
vention tools will remain ill informed.
Conclusions
Our analysis of the changes in malaria admissions across
Uganda show that the malaria transition witnessed in
some parts of Africa is not true of all of Africa. Uganda
is a long way from universal coverage of effective inter-
ventions, including ITN and access to effective treat-
ments. In areas where transmission intensity is high,
disease burdens remain high and most fevers will be
associated with malaria infection and ensuring more
than 80% coverage of interventions for prevention and
prompt treatment is critical. In these areas modest
increases in approaches to reduce infection risks or
treatment of suspected cases we suggest will not impact
on disease burdens to the same extent as proposed by
the LiST models [61,67] in areas of less intense trans-
mission and malaria morbidity and mortality is likely to
continue to rise.
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